Q3 2024 IHH Healthcare Bhd Earnings Call Transcript
Key Points
- IHH Healthcare Bhd (XKLS:5225) reported strong growth in core revenue and EBITDA, driven by higher patient volumes and increased revenue intensity across all markets.
- The company completed the acquisition of Island Hospital, enhancing its leadership position in Malaysia and supporting the country's medical tourism aspirations.
- IHH Healthcare implemented the CDC's antimicrobial stewardship guidelines across its 80-plus hospitals, making it the largest international private hospital network to do so.
- The company achieved double-digit growth in revenue, EBITDA, and PATMI on a year-to-date basis, excluding one-off items.
- IHH Healthcare successfully raised an unrated sukuk program for RMB4 billion, which was over four times oversubscribed, indicating strong investor demand.
- Margins in Malaysia fell by 100 basis points due to higher staff costs, despite an 11% revenue growth.
- Singapore operations faced margin pressure due to ongoing renovations at Mount Elizabeth Orchard, which reduced the number of operational beds.
- India's EBITDA and EBITDA margins declined by 3% year-on-year due to a one-off reversal of expenses in the previous year.
- The company faces ongoing challenges with third-party payers, including insurers, particularly in Malaysia, where medical inflation has been a concern.
- Translation impacts due to currency fluctuations affected the reported financial performance, with the ringgit's depreciation impacting results.
Ladies and gentlemen, good day, and welcome to third-quarter 2024 financial results of IHH Healthcare analyst briefing conference call. (Operator Instructions) I must advise you that this conference is being recorded today, November 28, 2024.
I'd now like to hand the call over to your first speaker today, Mr. Kelvin Chong from Investor Relations at IHH. Please go ahead, Mr. Chong.
Thank you. Good evening and thank you for joining us. I'm Kelvin from IHH Investor Relations. With me today is Dr. Prem, our group CEO; we have Mr. Dilip, our Group CFO; and Mr. Evren, is the Deputy CEO of Strategy and Business Development of Acibadem Turkish Operations. The materials that you see are also available on the IHH website for you to download.
We'll start the presentation of the 3Q results stood by an opening remark given by Dr. Prem. We will then move into the financial highlights by Dilip. Dr. Prem will then give an update on our key operating markets
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
